Last edition
News about Global Pharma
Celltrion Secures US FDA Approval for Expanded Indication for AVTOZMA
Celltrion has received FDA approval for an expanded indication of AVTOZMA IV (tocilizumab-anoh) to treat cytokine release syndrome (CRS), achieving full indication parity with reference biologic ACTEMRA IV in the US.
Global Pharma | 07/08/2025 | By Mrinmoy Dey | 253
Sandoz Reports Strong H1 2025 Results, Accelerated Growth in Biosimilars and Generics
Sandoz has reported strong financial results for the first half of the financial year 2025, with the company’s net sales reaching USD 5.2 billion. Growth accelerated in the second quarter, driven by solid performance across both the generics and biosimilars businesses.
Global Pharma | 07/08/2025 | By Dineshwori | 845
Intas Pharmaceuticals Acquires UDENYCA from Coherus BioSciences
Intas Pharmaceuticals, along with its global subsidiaries operating under the Accord brand, has acquired UDENYCA (pegfilgrastim-cbqv) from Coherus BioSciences, strengthening its global biosimilar portfolio and strengthening its position in the pegfilgrastim market.
Global Pharma | 07/08/2025 | By Mrinmoy Dey | 323
Kashiv Biosciences, MS Pharma Partner to Commercialise Xolair Biosimilar in MENA Region
Kashiv BioSciences and MS Pharma have entered into an exclusive licensing and supply agreement for the commercialization of ADL-018, Kashiv’s biosimilar candidate to XOLAIR (bOmalizumab) in the Middle East and North Africa (MENA) region.
Global Pharma | 07/08/2025 | By Dineshwori | 292
Sanofi Acquires Vigil Neuroscience, Strengthens Neurodegenerative Disease Pipeline
Sanofi has completed its acquisition of Vigil Neuroscience, thereby strengthening its early-stage pipeline in neurology with the addition of VG-3927, an experimental drug candidate for Alzheimer's disease.
Global Pharma | 07/08/2025 | By Dineshwori | 367
Pharmexcil Invites Indian Pharma Companies to Explore Opportunities in Mexico at Virtual Meet
The Pharmaceuticals Export Promotion Council of India (Pharmexcil) has invited its member companies to participate in a virtual meet on "Mexico: Expansion Opportunities for the Indian Pharmaceutical Industry."
Global Pharma | 06/08/2025 | By Dineshwori | 408
Intas Pharmaceuticals has launched HETRONIFLY (Serplulimab), the world’s first PD-1 inhibitor approved for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in the Indian market.
Global Pharma | 06/08/2025 | By Mrinmoy Dey | 522
Polpharma Biologics, Fresenius Kabi Partners to Commercialise A Proposed Vedolizumab Biosimilar
Polpharma Biologics, a European biotechnology company, has entered into a global licensing agreement with German multinational healthcare firm Fresenius Kabi for the commercialisation of PB016—a proposed biosimilar to vedolizumab.
Global Pharma | 06/08/2025 | By Dineshwori | 372
Governor of New York State Kathy Hochul has announced that Garonit Pharmaceutical, a global manufacturer of antiseptic products and health care solutions, will establish a state-of-the-art, 200,000-square-foot pharmaceutical manufacturing facility in New Windsor, Orange County.
Global Pharma | 05/08/2025 | By Dineshwori | 536
Viatris Appoints David Simmons to the Company's Board of Directors
Viatris Inc. has appointed seasoned pharma executive David Simmons to its Board of Directors, bringing decades of global leadership, R&D, and capital markets experience to support the company’s strategic growth.
Global Pharma | 05/08/2025 | By Mrinmoy Dey | 274
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy